Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma
NCT02296684Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Mar 2015
- Primary completion
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC) (2 cohorts), sponsored by Washington University School of Medicine. Primary endpoints: Locoregional Recurrence Rates in Cohorts 1 and 2 at 1 year, Distant Failure Rate in Cohorts 1 and 2 at 1 year and 1 more. Started Mar 2015; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02296684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02296684.